Tianjin Tianyao Pharmaceuticals (SHA:600488) secured registration approval for dexamethasone sodium phosphate active pharmaceutical ingredient (API) from Brazil's health surveillance agency.
Dexamethasone sodium phosphate is commonly used to treat allergies and autoimmune diseases, according to a Dec. 31 filing with the Shanghai bourse.
Shares of the company closed 1% lower Thursday.